Dr David Spigel reviews the results of key studies from 2020 on novel approaches to first- or second-line treatment of SCLC and mesothelioma with both existing and emerging agents.
Chief Scientific Officer; Director
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN
Related Items
JHOP - Supplements published on July 21, 2022 in Lung Cancer
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer